<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28332">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01795716</url>
  </required_header>
  <id_info>
    <org_study_id>YMTN-1.0</org_study_id>
    <nct_id>NCT01795716</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body</brief_title>
  <official_title>Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. purpose: To conduct the relative bioavailability study of a single dose and multiple
           doses of imatinib mesylate capsule (Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus
           Glivec (Novartis Pharma Stein AG).

        2. Experimental Design： Two-period crossover design

        3. Test drug: imatinib mesylate capsule Reference drug: Glivec

        4. Sample size：20
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To conduct the relative bioavailability study of a single dose and multiple doses of
      imatinib mesylate capsule(Jiangsu Chia-Tai Tianqing Pharmacy Co. Ltd.) versus Glivec
      (Novartis Pharma Stein AG) and compare the bioequivalence and pharmacokinetics of the two
      products in 20 patients with chronic myeloid leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Area Under Curve (AUC) Time Frame: predose, 0.5,1,1.5,2,3,5,8,12,24,48,72hours post-dose</measure>
    <time_frame>9 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>mesylate imatinib capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single and multiple oral mesylate imatinib capsule  400mg qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glivec</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single and multiple oral Glivec  400mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesylate imatinib capsule</intervention_name>
    <description>Single and multiple oral mesylate imatinib capsule   400mg qd</description>
    <arm_group_label>mesylate imatinib capsule</arm_group_label>
    <other_name>111201</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glivec</intervention_name>
    <description>Single and multiple oral Glivec  400mg qd</description>
    <arm_group_label>Glivec</arm_group_label>
    <other_name>Mesylate Imatinib tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic myeloid leukemia;

          -  Age: 18-65 years,gender:both.

          -  Weight: standard weight ± 20% within, and avoid weight disparity is too large;

          -  No previous radiation therapy, chemotherapy, or surgery within 1 weeks before
             treatment with imatinib;

          -  Performance status 0 to 3 (WHO scale); Life expectancy greater than 3 months;

          -  No other malignancy;

          -  Adequate hepatic, renal, and bone marrow function
             (WBC≥3.0×109/L，ANC≥1.5×109/L，PLT≥80×109/L. Serum bilirubin≤1.5×the institutional
             upper limit of normal, ALT、ALP≤2.5×the institutional upper limit of normal,
             creatinine≤1.5×the institutional upper limit of normal);

          -  Ability to understand objectives of the study, the study procedure, the
             pharmacological properties of the drug and possible adverse reactions and the
             willingness to sign a written informed consent.

        Exclusion Criteria:

          -  Suffering from heart, liver, kidney disease or severe acute and chronic
             gastrointestinal diseases;

          -  Pregnant or lactating women and be sensitive to drug;

          -  Subjects are thought unsuitable for the study by investigators;

          -  Inability to comply with protocol or study procedures in the opinion of the
             investigator;

          -  Attending other clinical trials or attended other clinical trials 3 months ago.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Zh xiang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Jiaotong University School of Medicine Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhou Li, doctor</last_name>
    <phone>13816510379</phone>
    <email>lizhou999_999@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou Li, doctor</last_name>
      <phone>13816510379</phone>
      <email>lizhou999_999@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Li zhou, doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 18, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Imatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
